Theranexus SA (FR:ALTHX) has released an update.
Theranexus partners with Synerlab to produce and commercialize its innovative pediatric miglustat oral solution for Niemann-Pick type C disease, targeting a 2026 market entry. This collaboration aims to address the unmet needs of pediatric patients and exploit a potential €200 million market in Europe. With lower financial requirements than other projects, Theranexus anticipates significant returns and market exclusivity.
For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.
